This trial is evaluating whether ABBV-400 will improve 1 primary outcome and 3 secondary outcomes in patients with Lung Cancer. Measurement will happen over the course of Up to 24 Months.
This trial requires 190 total participants across 7 different treatment groups
This trial involves 7 different treatments. ABBV-400 is the primary treatment being studied. Participants will be divided into 7 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Abbv-400 has been shown to be effective in reducing tumor size in animal models of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). In addition, abbv-400 has demonstrated antitumor effects in preclinical evaluations of breast cancer both as single agent therapy and combination therapy with other agents. Data from a recent study suggest that abbv-400 may represent a novel and promising anti-breast cancer therapeutic." - Anonymous Online Contributor
"The most common cause of carcinoma, non-small-cell lung is cigarette smoking (https://www.[cancer](https://www.withpower.com/clinical-trials/cancer).gov/about-carcinomas/causes/lung-carcinoma.html). Other risk factors include being exposed to secondhand smoke, air pollution (e.g., tobacco smoke), and occupational exposure to chemicals or radiation. When a patient smokes, take them to see their doctor regularly as this is a major factor in managing lung cancer. If a smoker has already had a lung cancer diagnosis, they need to stop smoking immediately because smoking will accelerate the spread of cancer cells. If you are considering joining a lung cancer clinical trial, [Power](http://www.withpower." - Anonymous Online Contributor
"The data show that there are many different treatments for carcinoma, non-small-cell lung (NSCLC). In addition, some of the treatments appear effective in NSCLC while others are ineffective. In view of the fact that no single treatment works well for all patients, we suggest that physicians consider initiating their patients on an appropriate combination of medications." - Anonymous Online Contributor
"Abbv-400 has demonstrated antitumor activity against both drug-sensitive and resistant HCC cell lines in vitro. Further evaluation on its antitumoral activity and tolerability will provide useful information for the development of future clinical trials." - Anonymous Online Contributor
"The present study suggests that radical surgery alone is not enough because there was no complete response rate found in patients who received chemotherapy only, compared with those who did not receive chemotherapy. Although the number of cases is very small, a prospective randomized controlled trial should be performed." - Anonymous Online Contributor
"Carcinoma, non-small-cell lung (CNSL) is a disease with heterogeneous clinical manifestations and varied biological behaviors depending on the stage of the disease at diagnosis. The present study showed that the expression of EMT markers was closely associated with the development of CNSL from adenocarcinomas, especially invasive adenocarcinoma." - Anonymous Online Contributor
"The speed of metastatic spread in NSCLC may be determined mainly by the length of time between diagnosis and therapy; however, other factors such as host-related variables also play a role." - Anonymous Online Contributor
"There is evidence suggesting that ABBV-400 reduces the rate of tumour growth in mice with established tumor xenografts. However, there is limited data on human tumors and further work is needed before ABBV-400 can be safely tested as a therapeutic agent in humans." - Anonymous Online Contributor
"There are more men with carcinoma and NSCLC In a recent study than women. In order to ascertain the true prevalence of these cancers in the US, the data obtained from this study should be compared with those obtained from previous studies of patients who underwent surgical resection for carcinoma. A nationwide survey should then be undertaken to assess the extent of the problem of carcinoma and NSCLC in the country." - Anonymous Online Contributor
"Carcinoma, non-small-cell lung appears to be genetically heterogeneous. In contrast to previous suggestions, our data indicate that genetic susceptibility to this disease does not seem to be inherited. Further studies are needed to identify the genes involved in lung cancer susceptibility." - Anonymous Online Contributor